In a recent report, analysts at Credit Suisse outlined their 2015 outlook for healthcare stocks. Here’s a breakdown of their top stocks to avoid in 2015.

1. United Therapeutics Corp UTHR 0.68%: Analysts expect the company to be under significant earnings pressure from expiring patents and generic competition. In addition, they see increased competition in the pulmonary arterial hypertension segment. Analysts expect that a relatively weak performance from the recently-launched Orenitram will not be a silver bullet for the company. Price target: $120.00
2. ARIAD Pharmaceuticals Inc ARIA 1.42%: Analysts give several factors holding back the company, including relatively flat IMS scripts and the potential for a net price reduction in H2:15. In addition, analysts believe the likelihood that ARIA is acquired by a larger company via a buyout is unlikely. Price target: $6.00
3. Amedisys Inc AMED 1.06%: After significant outperformance in 2014 based partially on buyout speculation and high short interest, analysts believe…

Read the rest of this article (and all my other articles) for free on Benzinga by clicking here

Want to learn more about the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!